$51.78 Million in Sales Expected for TESARO Inc (TSRO) This Quarter

Wall Street brokerages forecast that TESARO Inc (NASDAQ:TSRO) will post $51.78 million in sales for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for TESARO’s earnings, with estimates ranging from $46.07 million to $59.17 million. TESARO posted sales of $4.23 million in the same quarter last year, which would indicate a positive year over year growth rate of 1,124.1%. The company is scheduled to announce its next earnings report after the market closes on Tuesday, February 27th.

On average, analysts expect that TESARO will report full-year sales of $51.78 million for the current financial year, with estimates ranging from $221.37 million to $299.10 million. For the next fiscal year, analysts anticipate that the firm will post sales of $388.01 million per share, with estimates ranging from $274.00 million to $529.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for TESARO.

Several analysts recently commented on TSRO shares. Robert W. Baird reaffirmed a “hold” rating and set a $120.00 target price on shares of TESARO in a report on Friday, November 10th. Leerink Swann raised TESARO from a “market perform” rating to an “outperform” rating in a report on Wednesday, November 15th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $65.00 target price on shares of TESARO in a report on Thursday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 target price on shares of TESARO in a report on Monday, November 20th. Finally, Barclays started coverage on TESARO in a report on Monday, October 23rd. They set an “equal weight” rating and a $135.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. TESARO currently has a consensus rating of “Hold” and a consensus price target of $149.97.

TESARO (TSRO) opened at $58.31 on Tuesday. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $3,170.00, a PE ratio of -6.92 and a beta of 1.25. TESARO has a 1-year low of $57.82 and a 1-year high of $192.94.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 34.60% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC boosted its position in TESARO by 8.1% during the third quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after purchasing an additional 29,100 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of TESARO in the third quarter valued at approximately $33,911,000. California State Teachers Retirement System lifted its position in shares of TESARO by 20.8% in the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after acquiring an additional 11,706 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of TESARO by 22.9% in the second quarter. Voya Investment Management LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $2,001,000 after acquiring an additional 2,667 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its position in shares of TESARO by 379.4% in the third quarter. Vident Investment Advisory LLC now owns 5,652 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 4,473 shares in the last quarter.

WARNING: “$51.78 Million in Sales Expected for TESARO Inc (TSRO) This Quarter” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/06/51-78-million-in-sales-expected-for-tesaro-inc-tsro-this-quarter.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply